Skip to main content
. 2022 Mar 1;10(3):580. doi: 10.3390/biomedicines10030580

Figure 6.

Figure 6

Figure 6

Figure 6

(A) Drug-susceptibility profile of selected viral clones to evaluate the impact of the A314T, M656I, A684V, and L696S DNA polymerase substitutions. The source of the viral clones was as follows: A314T (VV8 HPMPDAP-R #8), A314T + A684V (VV8 HPMPC-R #30), A314T + L696S (VV11 #16), A314T + M656I + A684V (VV11 HPMPC-R #40), and A314T + A684V + L696S (VV11 HPMPDAP-R #39). (B) Drug-susceptibility profile of the selected VV11 HPMPO-DAPy-R viral clone bearing the G138E + A314T mutations. Drug-resistance properties of the different types of viral clones were determined using a CPE reduction assay with HEL fibroblasts. The effects of different drugs on viruses encoding the indicated mutations were determined by calculating the EC50 values for the parental wild-type strain and clones bearing the specific mutations. At least two independent experiments were performed for each test compound. Horizontal lines for each drug and mutant viral clones indicate the mean values ± standard deviation. The fold resistance (ratio of the EC50 for the mutant viruses to the EC50 for the corresponding wild-type virus is marked at the top of the graph. VACV viral clones showing a ≥2-fold increase (red, bold) were considered drug resistant (R) and those with a ≤0.5-fold decrease (orange, bold) drug hypersensitive (hs).